327 related articles for article (PubMed ID: 12456792)
41. Colocalization and ligand-dependent discrete distribution of the estrogen receptor (ER)alpha and ERbeta.
Matsuda K; Ochiai I; Nishi M; Kawata M
Mol Endocrinol; 2002 Oct; 16(10):2215-30. PubMed ID: 12351687
[TBL] [Abstract][Full Text] [Related]
42. Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-Relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells.
Bourgoin-Voillard S; Gallo D; Laïos I; Cleeren A; Bali LE; Jacquot Y; Nonclercq D; Laurent G; Tabet JC; Leclercq G
Biochem Pharmacol; 2010 Mar; 79(5):746-57. PubMed ID: 19879249
[TBL] [Abstract][Full Text] [Related]
43. Identification of novel estrogen receptor alpha antagonists.
Shao D; Berrodin TJ; Manas E; Hauze D; Powers R; Bapat A; Gonder D; Winneker RC; Frail DE
J Steroid Biochem Mol Biol; 2004 Apr; 88(4-5):351-60. PubMed ID: 15145444
[TBL] [Abstract][Full Text] [Related]
44. CoMSIA and docking study of rhenium based estrogen receptor ligand analogs.
Wolohan P; Reichert DE
Steroids; 2007 Mar; 72(3):247-60. PubMed ID: 17280694
[TBL] [Abstract][Full Text] [Related]
45. Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer.
Weatherman RV; Chang CY; Clegg NJ; Carroll DC; Day RN; Baxter JD; McDonnell DP; Scanlan TS; Schaufele F
Mol Endocrinol; 2002 Mar; 16(3):487-96. PubMed ID: 11875107
[TBL] [Abstract][Full Text] [Related]
46. Site-specific fluorescent labeling of estrogen receptors and structure-activity relationships of ligands in terms of receptor dimer stability.
Tamrazi A; Katzenellenbogen JA
Methods Enzymol; 2003; 364():37-53. PubMed ID: 14631838
[No Abstract] [Full Text] [Related]
47. Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release.
Gee AC; Katzenellenbogen JA
Mol Endocrinol; 2001 Mar; 15(3):421-8. PubMed ID: 11222743
[TBL] [Abstract][Full Text] [Related]
48. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta.
Sun J; Meyers MJ; Fink BE; Rajendran R; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 1999 Feb; 140(2):800-4. PubMed ID: 9927308
[TBL] [Abstract][Full Text] [Related]
49. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens.
Ekena K; Weis KE; Katzenellenbogen JA; Katzenellenbogen BS
J Biol Chem; 1997 Feb; 272(8):5069-75. PubMed ID: 9030571
[TBL] [Abstract][Full Text] [Related]
50. Binding Assays Using a Benzofurazan-Labeled Fluorescent Probe for Estrogen Receptor-Ligand Interactions.
Komatsu S; Ohno KI; Fujimura T
Chem Pharm Bull (Tokyo); 2020; 68(10):954-961. PubMed ID: 32999147
[TBL] [Abstract][Full Text] [Related]
51. Molecular modelling of the human estrogen receptor and ligand interactions based on site-directed mutagenesis and amino acid sequence homology.
Lewis DF; Parker MG; King RJ
J Steroid Biochem Mol Biol; 1995 Jan; 52(1):55-65. PubMed ID: 7857874
[TBL] [Abstract][Full Text] [Related]
52. William L. McGuire Memorial Symposium. Estrogen receptors: ligand discrimination and antiestrogen action.
Katzenellenbogen BS; Fang H; Ince BA; Pakdel F; Reese JC; Wooge CH; Wrenn CK
Breast Cancer Res Treat; 1993; 27(1-2):17-26. PubMed ID: 8260727
[TBL] [Abstract][Full Text] [Related]
53. Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach.
Puranik NV; Srivastava P; Bhatt G; John Mary DJS; Limaye AM; Sivaraman J
Sci Rep; 2019 May; 9(1):7450. PubMed ID: 31092862
[TBL] [Abstract][Full Text] [Related]
54. Temperature dependence of estrogen binding: importance of a subzone in the ligand binding domain of a novel piscine estrogen receptor.
Tan NS; Frecer V; Lam TJ; Ding JL
Biochim Biophys Acta; 1999 Nov; 1452(2):103-20. PubMed ID: 10559464
[TBL] [Abstract][Full Text] [Related]
55. A structural biologist's view of the oestrogen receptor.
Pike AC; Brzozowski AM; Hubbard RE
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):261-8. PubMed ID: 11162934
[TBL] [Abstract][Full Text] [Related]
56. CoMFA and docking study of novel estrogen receptor subtype selective ligands.
Wolohan P; Reichert DE
J Comput Aided Mol Des; 2003; 17(5-6):313-28. PubMed ID: 14635724
[TBL] [Abstract][Full Text] [Related]
57. Ligand dissociation from estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations.
Sonoda MT; Martínez L; Webb P; Skaf MS; Polikarpov I
Mol Endocrinol; 2008 Jul; 22(7):1565-78. PubMed ID: 18403716
[TBL] [Abstract][Full Text] [Related]
58. Chemical and biochemical issues related to X-ray crystallography of the ligand-binding domain of estrogen receptor alpha.
Goldstein SW; Bordner J; Hoth LR; Geoghegan KF
Bioconjug Chem; 2001; 12(3):406-13. PubMed ID: 11353539
[TBL] [Abstract][Full Text] [Related]
59. Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism.
Gangloff M; Ruff M; Eiler S; Duclaud S; Wurtz JM; Moras D
J Biol Chem; 2001 May; 276(18):15059-65. PubMed ID: 11278577
[TBL] [Abstract][Full Text] [Related]
60. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha.
Chakraborty S; Levenson AS; Biswas PK
BMC Struct Biol; 2013 Oct; 13():27. PubMed ID: 24160181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
